167 results about "Mood disorders" patented technology

The invention provides a method for constructing a mood disorder assessment model based on hierarchical multilevel gating, which comprises the following steps: acquiring electroencephalogram signals of a plurality of testees, labeling labels, and constructing a first training sample set; training by using the first training sample set to obtain time sequence dynamic graph network feature extraction models corresponding to the multiple electroencephalogram parameter combinations and related time sequence dynamic graph network features; constructing a second training sample set by using the first training sample set and the time sequence dynamic graph network features, and training a hierarchical multilevel gating model; and obtaining a mood disorder assessment model based on the time sequence dynamic graph network feature extraction model and the hierarchical multi-level gating model corresponding to each electroencephalogram parameter combination. According to the method, the problem that the assessment accuracy is limited due to the fact that a mood disorder assessment model in the prior art does not consider the correlation between different parameter combinations among the brain region, the frequency band and the observation time length and the task and does not perform hierarchical screening on different parameter brain networks based on the task correlation is solved.

The present invention relates to the use of mesembrine alkaloids for use in the treatment of mood disorders. In particular, the invention provides compositions and methods for improving symptoms associated with anxiety and / or mood disorders, or a disorder where anxiety and / or depression are comorbid.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

The invention provides a mood disorder assessment system based on multi-level feature fusion, and the system comprises a data collection unit which is used for collecting electroencephalogram signals of a plurality of brain regions of a to-be-assessed patient; the electroencephalogram feature extraction unit is used for extracting electroencephalogram features corresponding to the electroencephalogram signals of the brain regions; the multi-level feature extraction unit is constructed on the basis of the symptom features of the multiple testees and the corresponding electroencephalogram features, and is used for performing multi-level electroencephalogram feature latent variable extraction on the electroencephalogram features of the brain regions of the patient to be evaluated to obtain multi-level electroencephalogram feature latent variables; and the feature fusion and classification unit is used for carrying out classification prediction based on the electroencephalogram feature latent variables to obtain a mood disorder assessment result of the patient to be assessed. The method solves the problem that a mood disorder assessment system in the prior art adopts a single feature extraction and learning strategy and has no constraint of symptom information, so that the recognition capability of a model for mood disorders of different functional abnormality types is limited.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for improving cognition, emotion, memory and depression states and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by mass: radix scutellariae, rhizoma coptidis, radix puerariae, rhizoma anemarrhenae, bitter gourd, rhizoma zingiberis, stiff silkworm, American ginseng and radix notoginseng. Wherein the radix scutellariae and the rhizoma coptidis are monarch drugs and mainly attack the core pathogenesis; the radix puerariae, the rhizoma anemarrhenae and the pseudo-ginseng serve as ministerial drugs, assist monarch drugs and treat secondary pathogenesis; bitter gourd, rhizoma zingiberis, stiff silkworm and American ginseng are used as adjuvant drugs to regulate drug properties and treat and treat both symptoms and root causes; and radix puerariae and pseudo-ginseng are used as conductant drugs for guiding channels or harmonizing the drugs. The traditional Chinese medicine composition disclosed by the invention can be used for preventing and treating cognitive disorder, mood disorder and depressive state caused by metabolic disorder. The traditional Chinese medicine composition is small in side effect, high in individuation and suitable for being taken for a long time, and has an obvious treatment effect.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present invention relates to a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or nutritional compositions comprising the combination. The combination or compositions are for use in treating and / or preventing stress and / or a mood disorder in an infant, young child and / or child. The mixture of HMOs consists or consists essentially of 2′-fucosyllactose (2′FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6′ sialyllactose (6′SL). The present invention also relates to the use of a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or compositions comprising the combination, for treating and / or preventing stress and / or a mood disorder in an infant, young child and / or child, wherein the mixture of HMOs consists or consists essentially of 2′-fucosyllactose (2′FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6′ sialyllactose (6′SL).

Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, (I) can inhibit HCN1 / HCN2 and are expected to have utility as therapeutic agents, for example, for treating inhibiting, or ameliorating pain, such as, inflammatory and / or neuropathic pain, central nervous system (CNS) and psychiatric disorders, mood disorders, and tinnitus. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of, pain, such as, inflammatory and / or neuropathic pain, central nervous system (CNS) and psychiatric disorders, mood disorders, and tinnitus, and for preparing pharmaceuticals for this purpose.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The invention provides a multi-parameter fusion mood disorder assessment system based on a time sequence dynamic graph network, and the system comprises a data collection unit which is used for collecting an electroencephalogram signal of a to-be-assessed patient; the electroencephalogram coding unit is used for extracting electroencephalogram features corresponding to the electroencephalogram signals; the time sequence dynamic graph network feature extraction unit is used for constructing a time sequence dynamic graph network sequence related to various electroencephalogram parameter combinations and extracting related time sequence dynamic graph network features; the demographic information coding unit is used for coding the demographic information to obtain demographic coding features; and the hierarchical multi-level gating unit is used for predicting and obtaining a mood disorder evaluation result based on the sequential dynamic graph network characteristics corresponding to the electroencephalogram parameter combinations obtained by screening of the sequentially arranged multi-level gating layers. According to the method, the problem that in the prior art, a mood disorder evaluation system does not consider the correlation between multi-parameter combination and tasks and does not perform brain network model screening in a hierarchical gating mode, so that the evaluation accuracy is limited is solved.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as Parkinson's disease, psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present invention relates a method of treating attention-deficit / hyperactivity disorder (ADHD), wherein the patient suffers from mood disorders and / or anxiety. More specifically, the present invention is directed to a method of using a carbamate compound alone or in combination with other medications, for the treatment of ADHD.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Aspects of disclosure relate to a composition and methodology for treating menopause symptoms utilizing a cannabinoid-based nanoplatform composition. The composition includes phytocannabinoids like CBD, CBG, and CBN, alongside isoflavones and polyphenols, all integrated into nanoplatform designed for enhanced bioavailability and controlled release. The formulation is designed to alleviate key menopause-related issues, including vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), bone loss, mood disturbances, and sleep disorders, while addressing cardiovascular disease (CVD) risks. The composition combines cannabinoids, such as CBD, with isoflavones and polyphenols, and is incorporated into nanoplatforms for enhanced delivery and efficacy. Additionally, the disclosure includes a kit comprising oral capsules, intravaginal ovules, and instructions for use. The capsules contain a blend of cannabinoids, flavonoids, and polyphenols, while the ovules are composed of CBD and cocoa butter. The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.

This invention relates to the field of pharmaceutical technology, and discovers that the natural products boldinine and norboldinine can be used as NTSR1 (Neurotensin receptor-1, NTSR1) receptor antagonists and their applications. The compounds are boldinine and norboldinine ((+)-Laurolitsine), which have NTSR1 receptor antagonistic activity and are NTSR1 receptor antagonists that can prevent and treat alcohol poisoning, addiction, schizophrenia, autism spectrum disorder, and mood disorders. Accordingly, this invention can provide novel NTSR1 receptor antagonist prospective compounds with clear targets for the above-mentioned related diseases.

The invention relates to the field of medicines, and discloses a novel human PYY analogue, and compared with a PYY3-36 natural sequence, the novel human PYY analogue has a remarkable effect on improving metabolic diseases such as obesity, diabetes and fatty liver and emotional diseases such as anxiety disorder and depression.

A method for treating perinatal mood disorders in women diagnosed with or at risk for the perinatal mood disorders. The method includes administering a digital therapeutic to the subject, the digital therapeutic configured to provide cognitive behavioral therapy content to the subject to treat the perinatal mood disorders, wherein the perinatal mood disorders are treated, thereby causing the subject to exhibit an improvement upon completion of the cognitive behavioral therapy content relative to a control subject that was not administered the digital therapeutic. In some embodiments, the digital therapeutic can be administered in conjunction with a pharmacotherapeutic.

Blue light lumedome for control mood disorders

This invention discloses a method for screening or assessing the risk of GLP-1 receptor agonist-related mood disorders. It reveals for the first time that TTR is a key molecular switch for the bidirectional mood effects of GLP-1 receptor agonists, and its expression level needs to be maintained within a specific physiological window to ensure mood homeostasis. This invention assesses the risk of developing mood disorders after using GLP-1 receptor agonists by detecting the expression level or activity of TTR in subjects. This invention also provides kits for assessing the mood side effects of GLP-1 receptor agonists, methods for screening candidate drugs for the prevention or treatment of related mood disorders, and pharmaceutical compositions containing TTR or its agonists. This invention elucidates the molecular mechanism by which GLP-1 receptor agonists inhibit TTR expression through the cAMP / PKA / Gli3 signaling pathway, thereby affecting the ERK / CREB pathway and synaptic plasticity, providing novel targets and strategies for precise drug use, risk warning, and intervention for related mood disorders using GLP-1 receptor agonists.

The invention provides application of hippophae rhamnoides fruit extract in preparation of products for preventing and treating cognitive dysfunction and / or emotional disorder and improving memory, and belongs to the technical field of biological medicine. The invention provides application of a sea-buckthorn extract or a product containing the sea-buckthorn extract in preparation of a product for preventing and treating cognitive dysfunction and / or mood disorder and improving memory. The sea-buckthorn extract comprises sea-buckthorn fruit oil, sea-buckthorn seed oil and / or sea-buckthorn fruit pulp. The hippophae rhamnoides extract is prepared from natural food hippophae rhamnoides rich in nutrient substances, has remarkable prevention and treatment effects on cognitive dysfunction and / or emotional disorder, has the effect of improving memory, can replace traditional medicine treatment, and has the advantages of being small in side effect, economical, practical, suitable for being taken for a long time and good in compliance.

Methods and compositions are provided for treating or preventing a neurological disease or disorder using an inhibitor of Glyoxalase 1 (GLO1). In some embodiments, the inhibitor is a small molecule. In certain embodiments, the disease or disorder is a sleep disorder, a mood disorder such as depression, epilepsy, an anxiety disorder, substance abuse, substance dependence or substance such as an alcohol withdrawal syndrome.

The invention concerns methods for treating mood disorders such as depressive disorder or episodes, or other mood disorders with current depressive episodes, by administration of a leptin receptor agonist, such as metreleptin. The invention further shows amelioration of depressive disorder or episode and related conditions in patients suffering from depression as a primary disorder, or a depressive disorder or episode as a secondary disorder and / or comorbidity. The invention also concerns methods for treating a depressive episode, or a depressive disorder.

The invention discloses application of securinine in preparation of a medicine for relieving anxiety disorder of postmenopausal women. Female menopausal related mood disorder diseases are researched by constructing a bilateral ovariectomy mouse model, and mouse anxiety-like behaviors induced by ovariectomy can be quickly relieved within 30 minutes by single administration of a natural product securinine. The invention provides a medicine for treating postmenopausal female anxiety disorder, the medicine takes effect quickly, not only provides a brand new medicine candidate for quick intervention of menopausal related anxiety, but also defines a corresponding medication scheme, and has practical application potential.

The present disclosure discloses a composition of GLP-1 and PYY3-36 polypeptide analogues, a preparation method and use thereof, and relates to the technical field of biomedicines. The composition includes a GLP-1 polypeptide analogue and a PYY3-36 polypeptide analogue. Compared with the natural sequence of GLP-1 and the natural sequence of PYY3-36, the composition of the GLP-1 polypeptide analogue and the PYY3-36 polypeptide analogue has remarkable effects in ameliorating metabolic diseases such as obesity, diabetes mellitus, and fatty liver, and mood disorders such as anxiety and depression.

The present description relates to a method for treating a patient having a mood disorder, comprising administering to a subject in need a pharmaceutical composition comprising a base compound consisting substantially of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a pharmaceutically acceptable salt thereof in a specified dosage regimen.

5-HT2A receptor ligands and receptor-ligand complexes are synthesized. These ligands, which may link two indole containing moieties through an amine, may be used in therapeutically effective amounts, to treat mood disorders and neurologic disorders.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present disclosure provides a crystalline form of enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating mood disorders, neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using a crystalline form of enantiopure deuterium-enriched bupropion.

The invention relates to Witzia ciliaris capable of regulating mood health and relieving anxiety and an application of the Witzia ciliaris. The Witzia ciliaris is separated from a healthy human excrement sample. According to the present invention, the Witzia ciliata KY009 can regulate the levels of 5-hydroxytryptamine, brain-derived neurotrophic factors and cortisol so as to provide the anti-depression effect, can significantly reduce the contents of hippocampal proinflammatory factors such as IL-1beta, IL-6 and IFN-alpha, and has the neuroinflammation inhibition activity. The strain and the composition thereof can be used for preparing medicines for treating depression, functional foods for relieving depressive mood and health-care products for improving mood, play a therapeutic role by correcting immune imbalance state of a body and regulating neuroinflammation, and provide a new microbial intervention strategy for treatment of depression and related mood disorders.